Ma D, et al. - In the present study, the researchers sought to evaluate the performance of plasma glycated CD59 (pGCD59) as a biomarker of early gestational diabetes mellitus (GDM) and its correlation with delivering a large for gestational age (LGA) infant. In the DALI study, blood levels of pGCD59 were estimated in samples from 693 obese women (BMI > 29) who underwent a 75g, 2-hour oral glucose tolerance test at <20 weeks gestation: 486 individuals who had normal glucose tolerance throughout the pregnancy, 207 individuals who met GDM requirements at < 20 weeks and 77 individuals who were diagnosed with GDM during pregnancy week 24-28. In women with GDM < 20, mean pGCD59 levels were significantly higher than those without GDM. One unit increase in maternal pGCD59 level was linked to 36% increased odds of delivering a large for gestational age (LGA) infant. Findings suggested that pGCD59 is a simple and accurate biomarker for GDM detection in early pregnancy and LGA risk assessment.